✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹3,578 Cr.
P/E
50.63
About
RPG Life Sciences, a part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the Branded Formulations, Global Generics and Synthetic API… Read more
RPG Life Sciences, a part of RPG Enterprises, is an integrated pharmaceutical company operatin… Read more
Low
NA
52W Range
High
NA

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Product Wise Break-Up - Active Pharmaceutical Ingredients (API).

Product Wise Break-Up - Domestic Formulations

Location Wise Break-Up - International Formulations

Location Wise Break-Up

Customer Segment - International Formulations

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    • Gulshan Polyols Ltd.
    • Zim Laboratories Ltd.
    FAQs on RPG Life Sciences Ltd. Business

    RPG Life Sciences is a research-based pharmaceutical company under RPG Enterprises. It operates in Branded Formulations, Global Generics, and Synthetic APIs markets, producing a wide range of quality and affordable medicines.

    RPG Life Sciences major competitors are Alembic, Guj. Themis Biosyn, Solara Active Pharma, Advanced Enzyme, Indoco Remedies, Dishman Carbogen Amc, Suven Life Sciences.
    Market Cap of RPG Life Sciences is ₹3,578 Crs.
    While the median market cap of its peers are ₹3,260 Crs.

    RPG Life Sciences seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Dec Jun Dec Jun Dec Mar Jun Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis